AVROBIO, Inc. (AVRO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about AVROBIO, Inc. (AVRO)
Go deeper and ask any question about AVRO
Company Performance
Current Price
as of Sep 13, 2024$17.99
P/E Ratio
N/A
Market Cap
$265.07M
Description
AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA.
Metrics
Overview
- HQWatertown, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerAVRO
- Price$17.99+2.80%
Trading Information
- Market Cap$265.07M
- Float79.62%
- Average Daily Volume (1m)26,635
- Average Daily Volume (3m)38,097
- EPS-$14.34
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$12.67M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$11.16M
- EV-$133.59M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account